首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2496666篇
  免费   193185篇
  国内免费   5509篇
耳鼻咽喉   34711篇
儿科学   83319篇
妇产科学   69852篇
基础医学   355915篇
口腔科学   68743篇
临床医学   220396篇
内科学   496066篇
皮肤病学   57073篇
神经病学   201719篇
特种医学   95389篇
外国民族医学   1054篇
外科学   372812篇
综合类   55919篇
现状与发展   6篇
一般理论   800篇
预防医学   200513篇
眼科学   57295篇
药学   182410篇
  5篇
中国医学   6002篇
肿瘤学   135361篇
  2021年   19445篇
  2019年   20848篇
  2018年   30046篇
  2017年   22320篇
  2016年   24699篇
  2015年   27838篇
  2014年   38590篇
  2013年   57694篇
  2012年   80256篇
  2011年   84957篇
  2010年   49767篇
  2009年   46482篇
  2008年   78378篇
  2007年   83343篇
  2006年   83538篇
  2005年   81074篇
  2004年   77860篇
  2003年   74479篇
  2002年   72498篇
  2001年   119096篇
  2000年   122870篇
  1999年   103201篇
  1998年   28775篇
  1997年   25861篇
  1996年   26154篇
  1995年   24824篇
  1994年   22882篇
  1993年   21383篇
  1992年   79371篇
  1991年   76567篇
  1990年   73998篇
  1989年   70517篇
  1988年   64876篇
  1987年   63558篇
  1986年   59473篇
  1985年   56938篇
  1984年   43150篇
  1983年   36386篇
  1982年   21690篇
  1981年   19466篇
  1979年   38671篇
  1978年   27067篇
  1977年   22759篇
  1976年   21455篇
  1975年   22783篇
  1974年   27113篇
  1973年   26241篇
  1972年   24377篇
  1971年   22164篇
  1970年   21055篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
93.
目的探讨腹腔镜经腹腹膜前疝修补术(TAPP)放置腹膜前引流对术后血肿及血清肿的影响。 方法选取2016年6月至2018年5月,江苏省苏州市中西医结合医院收治的单侧腹股沟疝患者90例,随机分为试验组和对照组,2组患者均行TAPP手术。试验组放置腹膜前引流管,对照组不放置引流管。收集2组患者的一般资料、手术相关资料及随访资料进行统计学分析,对比2组患者术后血肿及血清肿发生率差异。 结果全部患者均完成手术及随访。2组患者的一般资料、疝位置、疝分型、手术时间、住院花费、术后住院时间差异无统计学意义(P>0.05)。2组患者的术后发热发生率、急性疼痛发生率差异无统计学意义(P>0.05)。试验组术后血肿发生率明显低于对照组(P<0.05),试验组患者术后1和3个月血清肿发生率明显低于对照组,差异有统计学意义(P<0.05)。2组患者1年随访均观察到1例复发的病例,差异无统计学意义(P>0.05);随访期内2组患者均未出现感染的病例。 结论TAPP中,放置腹膜前引流管能够有效降低患者术后血肿和血清肿的发生率,同时并不增加感染和复发风险。  相似文献   
94.
Pharmaceutical Chemistry Journal - Three extracts were produced from the above-ground part of the meadowsweet Filipendula ulmaria (L.) Maxim. using water, 40% ethanol, and 70% ethanol. Comparative...  相似文献   
95.
96.
Behçet disease is a complex, multisystem disease characterized by recurrent oral and genital ulcerations. It rarely occurs in infants or children. Neonatal Behçet disease has been reported in infants whose ulcers resolve at or before 9 weeks of age. Few cases of neonatal Behçet disease persisting into childhood have previously been reported. We report the case of a 1‐month‐old infant who presented with severe recurrent genital ulcerations and at 6 months developed recurrent oral ulcerations. Her orogenital ulcerations continue to recur. Human leukocyte antigen testing revealed HLA‐B51 and B44 positivity. This is a case of pediatric Behçet disease in the neonatal period. Behçet disease should be considered in the differential diagnosis of recurrent genital and oral ulcerations in infants and children.  相似文献   
97.
98.
AimsWe previously showed that the protective effects of endothelial progenitor cells (EPCs)‐released exosomes (EPC‐EXs) on endothelium in diabetes. However, whether EPC‐EXs are protective in diabetic ischemic stroke is unknown. Here, we investigated the effects of EPC‐EXs on diabetic stroke mice and tested whether miR‐126 enriched EPC‐EXs (EPC‐EXsmiR126) have enhanced efficacy.MethodsThe db/db mice subjected to ischemic stroke were intravenously administrated with EPC‐EXs 2 hours after ischemic stroke. The infarct volume, cerebral microvascular density (MVD), cerebral blood flow (CBF), neurological function, angiogenesis and neurogenesis, and levels of cleaved caspase‐3, miR‐126, and VEGFR2 were measured on day 2 and 14.ResultsWe found that (a) injected EPC‐EXs merged with brain endothelial cells, neurons, astrocytes, and microglia in the peri‐infarct area; (b) EPC‐EXsmiR126 were more effective than EPC‐EXs in decreasing infarct size and increasing CBF and MVD, and in promoting angiogenesis and neurogenesis as well as neurological functional recovery; (c) These effects were accompanied with downregulated cleaved caspase‐3 on day 2 and vascular endothelial growth factor receptor 2 (VEGFR2) upregulation till day 14.ConclusionOur results indicate that enrichment of miR126 enhanced the therapeutic efficacy of EPC‐EXs on diabetic ischemic stroke by attenuating acute injury and promoting neurological function recovery.  相似文献   
99.
100.

Researchers have highlighted numerous sociocultural factors that have been shown to underpin human appearance enhancement practices, including the influence of peers, family, the media, and sexual objectification. Fewer scholars have approached appearance enhancement from an evolutionary perspective or considered how sociocultural factors interact with evolved psychology to produce appearance enhancement behavior. Following others, we argue that evidence from the field of evolutionary psychology can complement existing sociocultural models by yielding unique insight into the historical and cross-cultural ubiquity of competition over aspects of physical appearance to embody what is desired by potential mates. An evolutionary lens can help to make sense of reliable sex and individual differences that impact appearance enhancement, as well as the context-dependent nature of putative adaptations that function to increase physical attractiveness. In the current review, appearance enhancement is described as a self-promotion strategy used to enhance reproductive success by rendering oneself more attractive than rivals to mates, thereby increasing one’s mate value. The varied ways in which humans enhance their appearance are described, as well as the divergent tactics used by women and men to augment their appearance, which correspond to the preferences of opposite-sex mates in a heterosexual context. Evolutionarily relevant individual differences and contextual factors that vary predictably with appearance enhancement behavior are also discussed. The complementarity of sociocultural and evolutionary perspectives is emphasized and recommended avenues for future interdisciplinary research are provided for scholars interested in studying appearance enhancement behavior.

  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号